In addition to anti‐angiogenic activity, both broussonin A and B have anti‐proliferative and anti‐invasive activities against NSCLC and ovarian cancer cells concomitant with suppression of integrin β1 expression, independently of p53 levels. This evidence concerns the gene TP53 and ovarian carcinoma.